Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.
Horbach IS, de Souza Azevedo A, Schwarcz WD, Alves NDS, de Moura Dias B, Setatino BP, da Cruz Moura L, de Souza AF, Denani CB, da Silva SA, Pimentel TG, de Oliveira Silva Ferreira V, Azamor T, Ano Bom APD, da Penha Gomes Gouvea M, Mill JG, Valim V, Polese J, Campi-Azevedo AC, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, de Lima SMB, de Sousa Junior IP. Horbach IS, et al. Among authors: denani cb. Diseases. 2024 Jan 18;12(1):29. doi: 10.3390/diseases12010029. Diseases. 2024. PMID: 38248380 Free PMC article.
Inhibition of SARS-CoV-2 Infection in Vero Cells by Bovine Lactoferrin under Different Iron-Saturation States.
Alves NS, Azevedo AS, Dias BM, Horbach IS, Setatino BP, Denani CB, Schwarcz WD, Lima SMB, Missailidis S, Ano Bom APD, Silva AMV, Barreto Vieira DF, Silva MAN, Barros CA, Carvalho CAM, Gonçalves RB. Alves NS, et al. Among authors: denani cb. Pharmaceuticals (Basel). 2023 Sep 25;16(10):1352. doi: 10.3390/ph16101352. Pharmaceuticals (Basel). 2023. PMID: 37895823 Free PMC article.
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
Azamor T, Horbach IS, Brito E Cunha D, Melgaço JG, Silva AMVD, Tubarão LN, Azevedo AS, Santos RT, Alves NDS, Machado TL, Silva J, Souza AF, Bayma C, Rocha VP, Frederico ABT, Dias BM, Setatino BP, Denani CB, Campos SPDC, Schwarcz WD, Sucupira MV, Mendes EP, Silva EDD, Barbosa de Lima SM, Ano Bom APD, Missailidis S. Azamor T, et al. Among authors: denani cb. Viruses. 2022 Aug 30;14(9):1916. doi: 10.3390/v14091916. Viruses. 2022. PMID: 36146723 Free PMC article.
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
Valim V, Martins-Filho OA, Gouvea MDPG, Camacho LAB, Villela DAM, de Lima SMB, Azevedo AS, Neto LFP, Domingues CMAS, de Medeiros Junior NF, Moulaz IR, Dias LH, Miyamoto ST, Teixeira-Carvalho A, Mill JG; Half Dose ChAdOx Study Group. Valim V, et al. Front Immunol. 2022 Aug 29;13:966416. doi: 10.3389/fimmu.2022.966416. eCollection 2022. Front Immunol. 2022. PMID: 36105814 Free PMC article. Clinical Trial.
Lactoferrin affects rhinovirus B-14 entry into H1-HeLa cells.
Denani CB, Real-Hohn A, de Carvalho CAM, Gomes AMO, Gonçalves RB. Denani CB, et al. Arch Virol. 2021 Apr;166(4):1203-1211. doi: 10.1007/s00705-021-04993-4. Epub 2021 Feb 19. Arch Virol. 2021. PMID: 33606112 Free PMC article.